LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...

07:59 AM EST, 03/04/2026 (MT Newswires) -- The broad tone across global markets is a bit more positive early Wednesday, said Scotiabank. Oil prices are up by either side of 1% for WTI and Brent, but slight optimism shines elsewhere, noted the bank. United States equity futures are marginally positive, TSX futures more so, and European equity cash markets are...

LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...

07:59 AM EST, 03/04/2026 (MT Newswires) -- Fennec Pharmaceuticals ( FENC ) said Wednesday that the Tampa General Hospital, or TGH, Cancer Institute is launching a study on the real-world clinical utility of Pedmark in reducing the risk of ototoxicity in adolescent, young adult and adult cancer patients receiving cisplatin-based treatment. Pedmark, or sodium thiosulfate injection, is approved in the...